ZURICH--(BUSINESS WIRE)--AL-S Pharma AG, a clinical-stage biotechnology company discovering and developing human antibodies that target misfolded proteins implicated in amyotrophic lateral sclerosis (ALS), today announced the presentation of clinical data from the global Phase 2 clinical trial (AP-101-02) evaluating the company’s Phase 3-ready lead program, AP-101, in patients with ALS. The AP-101-02 clinical trial results were featured today in a poster presentation at the European Network to